The present disclosure relates generally to certain tricyclic compounds, pharmaceutical compositions comprising said compounds, and methods of making said compounds and pharmaceutical compositions. The compounds of the disclosure are useful in treating or preventing human immunodeficiency virus (HIV) infection.

The present invention relates to macrocyclic indole derivatives of general formula (I): ##STR00001##
in which R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6, A and L are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds, and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of hyperproliferative disorders, as a sole agent or in combination with other active ingredients.

The present invention relates to macrocyclic indole derivatives of general formula (I): ##STR00001##
in which R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6, A and L are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds, and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of hyperproliferative disorders, as a sole agent or in combination with other active ingredients.

The disclosure relates to USP30 Inhibitor Compounds, pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising same, and medical uses involving same.

The disclosure relates to USP30 Inhibitor Compounds, pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising same, and medical uses involving same.

The present disclosure relates to compounds and salts thereof that are useful for modulating target polypeptides and proteins, in particular BRM. Also disclosed are pharmaceutical compositions comprising the compounds, or a salt (e.g., a pharmaceutically acceptable salt) thereof, and methods of using such compounds and salts in the treatment of various BRM-mediated and/or BRG1-mediated diseases or disorders.

Novel N2-phenylpyrimidine-2,4-diamine compounds, method for preparing the same, and pharmaceutical composition or health functional food are disclosed. The novel N2-phenylpyrimidine-2,4-diamine compounds show potent inhibitory efficacies on EGFR mutations and thus, can be effectively used for the treatment of cancer with EGFR mutations.

Novel N2-phenylpyrimidine-2,4-diamine compounds, method for preparing the same, and pharmaceutical composition or health functional food are disclosed. The novel N2-phenylpyrimidine-2,4-diamine compounds show potent inhibitory efficacies on EGFR mutations and thus, can be effectively used for the treatment of cancer with EGFR mutations.

The present invention provides a novel compound that has anti-RSV activity and that is useful in the prevention or treatment of an infection in which viruses of the subfamily Pneumovirinae, including respiratory syncytial virus (RSV), are involved, or a pharmaceutically acceptable salt thereof. Specifically, the present invention provides a compound represented by formula (I):

##STR00001##

or a pharmaceutically acceptable salt thereof.

Tricyclic compounds and their use are provided. More specifically, tricyclic compounds, pharmaceutical compositions containing them, methods for preparing them, and their use in therapy are also provided.